Actinium Pharmaceuticals Stock Price

-0.08 (-1.4%)
Upgrade to Real-Time
Regular Market
Volume 5,866
Bid Price
Ask Price
News -
Day High 5.70


52 Week Range


Day Low 5.65
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Actinium Pharmaceuticals Inc ATNM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -1.4% 5.65 09:30:02
Open Price Low Price High Price Close Price Prev Close
5.70 5.65 5.70 5.73
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
21 5,866 $ 5.70 $ 33,436 - 4.41 - 10.30
Last Trade Time Type Quantity Stock Price Currency
09:30:03 1 $ 5.695 USD


Draw Mode:

Actinium Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 134.86M 23.78M 23.78M $ 1.14M $ - -1.20 -5.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.44M 1.80%

more financials information »

Actinium Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATNM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.955.744.805.32118,4760.7014.14%
1 Month5.255.744.735.0990,2280.407.62%
3 Months5.416.344.675.31136,1150.244.44%
6 Months5.307.494.416.32503,5850.356.6%
1 Year6.9110.304.416.57338,996-1.26-18.23%
3 Years0.216813.18210.15060.9909222,730,8425.432,506.09%
5 Years0.6513.18210.15060.89810822,065,3975.00769.23%

Actinium Pharmaceuticals Description

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Your Recent History
Actinium P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now